Skip to search formSkip to main contentSkip to account menu

metastatic colorectal cancer

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study
SummaryBackground Bevacizumab significantly improves progression-free survival (PFS) and overall survival (OS) when added to… 
2010
2010
Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).
3528^ Background: Pmab is a fully human antiepidermal growth factor receptor (EGFR) monoclonal antibody approved as monotherapy… 
2010
2010
Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic…
3530 Background: GDC-0449 is an HPI that has shown clinical activity in advanced basal cell carcinoma and preclinical activity in… 
2010
2010
A phase I dose escalation study of BIBF 1120 combined with FOLFOX in metastatic colorectal cancer (mCRC) patients (pts).
e14054 Background: BIBF 1120 is a potent oral triple angiokinase inhibitor targeting VEGFR 1–3, PDGFR α and β and FGFR 1–3. BIBF… 
2010
2010
Hypertension and survival in unresectable metastatic colorectal cancer (mCRC) patients receiving first-line bevacizumab (BEV) and FOLFOX.
e14066 Background: BEV combined with chemotherapy (CT) has shown to be efficacious for treatment of a variety of malignancies. A… 
2010
2010
FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo…
3543 Background: The combination of BV with cytotoxic drugs is an efficacious strategy in the treatment of mCRC. The triple drug… 
2008
2008
Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966
4022 Background: Resection of initially unresectable metastatic lesions in pts with mCRC who have responded to systemic therapy… 
2008
2008
First-line treatment with bevacizumab plus capecitabine for elderly patients with metastatic colorectal cancer: BECA trial
15120 Background: Elderly pts with metastatic colorectal cancer (mCRC) are frequently treated with Capecitabine (Cap) alone if… 
2008
2008
Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group
4033 Background: Cetuximab combined with 5-fluorouracil/folinic acid (5-FU/FA) plus irinotecan or oxaliplatin has shown activity… 
2007
2007
Institutional experiences with panitumumab monotherapy in metastatic colorectal cancer (mCRC) patients (pts) intolerant to cetuximab
14579 Background: Two monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor are approved for the treatment…